Drugs / 4G7xH22
last change Feb 2003 re-read 2 minutes ago

4G7xH22

Monoclonal antibody

Developed for
leukemia · lymphoma
Investigated by
Dartmouth-Hitchcock Medical Center · National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00014560 Sep 2000 → Feb 2003 leukemia, lymphoma Dartmouth-Hitchcock Medical Center Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 4G7xH22 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00014560
Modality Monoclonal antibody “bispecific antibody 4G7xH22” NCT00014560
Route Intravenous “BsAb 4G7xH22 IV over 2 hours” NCT00014560